SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : MGI Pharma MOGN New patents, anti cancer
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: seminole who wrote (999)5/19/1998 7:55:00 PM
From: Russian Bear  Read Replies (2) of 1826
 
Richard,

Despite the fact that this is not really news (neither was the last bit of "news,") I think that Dr. Eckhardt's comments will be understood to be a strong positive for 114. After all, what else could we have hoped for from a Phase I, other than the establishment of a toxicity profile mild enough to achieve significant serum concentrations prior to hitting the MTD?

The more I think about it, the more I am inclined to agree with your "wait until they actually shrink a tumor" approach. Perhaps by this time next year, (am I being too optimistic with regard to the timeframe?) we could have some preliminary data from one or more of the upcoming Phase II studies. If results are positive, it could make ENMD's little trip from 12 to 85 look tame by comparison.

Take care,
RB
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2026 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News